CHRS - Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal
2024-01-22 02:48:40 ET
More on Coherus BioSciences, Sandoz Group:
- Coherus BioSciences: FDA Approvals Spice Up The Pipeline
- Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval
- Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028
- Coherus spikes after mid-stage data for liver cancer therapy
- Coherus ends Junshi-partnered TIGIT Program in portfolio shakeup
For further details see:
Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal